Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males

• Main Authors: Wendy Ankrom (Author), Phung Bondiskey (Author), Chi‐Chung Li (Author), John Palcza (Author), Wen Liu (Author), Marissa F. Dockendorf (Author), Catherine Matthews (Author), Deborah Panebianco (Author), Tom Reynders (Author), John A. Wagner (Author), Abhijeet Jakate (Author), Sofie Mesens (Author), Walter K. Kraft (Author), Eugene E. Marcantonio (Author)
• Format: Book
• Published: Wiley, 2020-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ubrogepant is a novel, oral calcitonin gene‐related peptide (CGRP) receptor antagonist intended for the acute treatment of migraine attacks. Ubrogepant has a chemical structure distinct from previous small‐molecule CGRP receptor antagonists that were associated with elevated serum alanine aminotrans...